v3.23.2
License, Collaboration and Other Significant Agreements - Mitsubishi Tanabe Pharma Corporation Collaboration Agreement Narrative (Details)
 3 Months Ended 12 Months Ended 36 Months Ended
Dec. 11, 2015
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Dec. 31, 2022
USD ($)
performance_obligation
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2022
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Recognized revenue under agreement         $ 292,484,000 $ 211,650,000 $ 294,644,000    
Deferred revenue, net of current portion         43,296,000 21,474,000     $ 43,296,000
Deferred revenue         47,034,000       47,034,000
Short-term deferred revenue         3,738,000 20,906,000     3,738,000
Revenue recognized         29,574,000 23,364,000 36,032,000    
Accounts receivable                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Accounts receivable         1,901,000 19,094,000 3,045,000   1,901,000
License, collaboration and other revenue                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Recognized revenue under agreement         115,535,000 71,362,000 166,406,000    
Mitsubishi Tanabe Pharma Corporation                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Recognized revenue under agreement         1,800,000 800,000 400,000   3,000,000
Mitsubishi Tanabe Pharma Corporation | License, collaboration and other revenue                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Recognized revenue under agreement         17,968,000 12,438,000 15,405,000 $ 10,000,000  
Mitsubishi Tanabe Pharma Corporation | Regulatory Milestone, Approval Of Vadadustat In Japan                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Recognized revenue under agreement             15,000,000    
Mitsubishi Tanabe Pharma Corporation | Regulatory Milestone Payments                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Milestone revenue         $ 25,000,000        
Recognized revenue under agreement       $ 10,000,000          
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Collaboration Agreement, Global Phase 3 Program                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Proceeds from collaborators $ 0                
Mitsubishi Tanabe Pharma Corporation | MTPC                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Collaboration agreement, expiration period         10 years        
Collaboration agreement, notice period for termination         12 months        
Additional milestone or royalty payments received         $ 0        
Number of performance obligations | performance_obligation         2        
Deferred revenue, net of current portion         $ 0       0
Deferred revenue         3,738,000       3,738,000
Short-term deferred revenue         $ 3,738,000       3,738,000
Mitsubishi Tanabe Pharma Corporation | MTPC | Maximum                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Percentage of royalty payments on sales         20.00%        
Mitsubishi Tanabe Pharma Corporation | MTPC | Minimum                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Percentage of royalty payments on sales         13.00%        
Mitsubishi Tanabe Pharma Corporation | MTPC | Regulatory Milestone Payments                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Milestone revenue   $ 15,000,000     $ 25,000,000        
Mitsubishi Tanabe Pharma Corporation | MTPC | Regulatory Milestone Payments | Maximum                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Upfront cash payment received         40,000,000        
Mitsubishi Tanabe Pharma Corporation | MTPC | Development, Regulatory and Commercial Events | Maximum                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Potential milestone revenue         225,000,000        
Mitsubishi Tanabe Pharma Corporation | MTPC | Development Milestones                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Milestone revenue         10,000,000        
Mitsubishi Tanabe Pharma Corporation | MTPC | Commercial Milestone Payments | Maximum                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Potential milestone revenue (up to)         175,000,000        
Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Research And License Agreement                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Upfront cash payment received         20,000,000        
Incurred clinical and commercial development cost         20,500,000        
Cost of research services         20,500,000        
Accounts receivable         0       0
Deferred revenue         0       0
Mitsubishi Tanabe Pharma Corporation | Development And Commercialize Research And License Agreement | Accounts receivable                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Accounts receivable         600,000       600,000
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Upfront cash payment received     $ 10,400,000            
Deferred revenue, net of current portion         0       0
Revenue recognized         0 0 6,200,000    
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited | Accounts receivable                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Accounts receivable         0       0
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited | Other Current Liabilities                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Short-term deferred revenue         0       0
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited | Other Noncurrent Liabilities                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Deferred revenue, net of current portion         0       0
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Deferred revenue, net of current portion         3,700,000       3,700,000
Revenue recognized         16,200,000 $ 11,600,000 $ 0    
Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Corporation Supply Agreement | Accounts receivable                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Accounts receivable         $ 2,100,000       $ 2,100,000